

TENNESSEE Diabetes Data & Forecasts



State Total Population Forecasts	2015	2020	2025	2030
Entire Population	6,502,000	6,780,700	7,073,100	7,380,600
Prediabetes	1,764,900	1,901,300	2,042,600	2,134,300
Diagnosed diabetes	586,600	724,600	849,800	957,500
Undiagnosed diabetes	183,300	215,000	239,300	255,400
Total with diabetes (diagnosed and undiagnosed)	769,900	939,600	1,089,000	1,212,900
Complications:				
Visual impairment	96,200	115,400	131,300	143,600
Renal failure	1,400	1,670	1,890	2,050
Leg amputations	1,210	1,380	1,490	1,540
Annual deaths attributable to diabetes	6,320	7,450	8,300	8,850
Total annual cost (2015 dollars)	\$7.6 B	\$9.2 B	\$10.6 B	\$11.8 B
Annual medical costs	\$5.6 B	\$6.7 B	\$7.8 B	\$8.6 B
Annual nonmedical costs	\$2.0 B	\$2.5 B	\$2.8 B	\$3.2 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	968,900	1,121,100	1,280,000	1,417,700
Prediabetes	494,100	571,700	652,800	723,000
Diagnosed diabetes	183,100	211,900	241,900	267,900
Undiagnosed diabetes	67,800	78,500	89,600	99,200
Total with diabetes (diagnosed and undiagnosed)	251,000	290,400	331,500	367,200
Complications:				
Visual impairment	34,300	38,600	43,000	46,400
Renal failure	560	630	700	740
Leg amputations	420	450	480	490
Annual deaths attributable to diabetes	4,360	4,990	5,390	5,580
Total annual cost (2015 dollars)	\$3.2 B	\$3.7 B	\$4.2 B	\$4.7 B
Annual medical costs	\$3.0 B	\$3.5 B	\$4.0 B	\$4.4 B
Annual nonmedical costs	\$0.2 B	\$0.2 B	\$0.2 B	\$0.3 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.